Key questions about the checkpoint blockade-are microRNAs an answer?

The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early phase 3 clinical trials. The therapeutic indicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragomir, Mihnea, Chen, Baoqing, Fu, Xiao, Calin, George A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994554/
https://www.ncbi.nlm.nih.gov/pubmed/29951335
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994554/
https://www.ncbi.nlm.nih.gov/pubmed/29951335
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0006

Ejemplares similares